Join APEX trial investigator Dr Russell Hull for a discussion of the latest substudy exploring betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically in patients, originally presented at ESC 2018.
Register your email and provide your feedback
To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey
Admittance of a patient to the intensive care unit (ICU) is a predictor of venous thromboembolism. In this informative journal club, Dr Russell Hull provides insights into the latest APEX trial retrospective analysis looking at extended-duration prophylaxis by betrixaban, and whether this novel regimen yielded clinical benefit with respect to reduced bleeding and VTE risk when compared with the current standard of care by enoxaparin.